Bartalena L, Tanda ML (2022) Current concepts regarding graves’ orbitopathy. J Intern Med 292:692–716. https://doi.org/10.1111/joim.13524

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chin YH, Ng CH, Lee MH, Koh JWH, Kiew J, Yang SP, Sundar G, Khoo CM (2020) Prevalence of thyroid eye disease in graves’ disease: A meta-analysis and systematic review. Clin Endocrinol (Oxf) 93:363–374. https://doi.org/10.1111/cen.14296

Article  PubMed  Google Scholar 

Hoang TD, Stocker DJ, Chou EL, Burch HB (2022) 2022 Update on clinical management of graves disease and thyroid eye disease. Endocrinol Metab Clin North Am 51:287–304. https://doi.org/10.1016/j.ecl.2021.12.004

Article  PubMed  PubMed Central  Google Scholar 

Wiersinga WM (2017) Advances in treatment of active, moderate-to-severe graves’ ophthalmopathy. Lancet Diabetes Endocrinol 5:134–142. https://doi.org/10.1016/s2213-8587(16)30046-8

Article  CAS  PubMed  Google Scholar 

Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC (2016) TSH/IGF-1 receptor cross talk in graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab 101:2340–2347. https://doi.org/10.1210/jc.2016-1315

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, Kahaly GJ, Ludgate M (2020) New insights into the pathogenesis and nonsurgical management of graves orbitopathy. Nat Rev Endocrinol 16:104–116. https://doi.org/10.1038/s41574-019-0305-4

Article  CAS  PubMed  Google Scholar 

Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM (2021) The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves’ orbitopathy. Eur J Endocrinol 185:G43–g67. https://doi.org/10.1530/eje-21-0479

Article  CAS  PubMed  Google Scholar 

Längericht J, Krämer I, Kahaly GJ (2020) Glucocorticoids in graves’ orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab 11:2042018820958335. https://doi.org/10.1177/2042018820958335

Article  CAS  PubMed  PubMed Central  Google Scholar 

He Y, Mu K, Liu R, Zhang J, Xiang N (2017) Comparison of two different regimens of intravenous Methylprednisolone for patients with moderate to severe and active graves’ ophthalmopathy: a prospective, randomized controlled trial. Endocr J 64:141–149. https://doi.org/10.1507/endocrj.EJ16-0083

Article  CAS  PubMed  Google Scholar 

Moleti M, Giuffrida G, Sturniolo G, Squadrito G, Campennì A, Morelli S, Puxeddu E, Sisti E, Trimarchi F, Vermiglio F, Marinò M (2016) Acute liver damage following intravenous glucocorticoid treatment for graves’ ophthalmopathy. Endocrine 54:259–268. https://doi.org/10.1007/s12020-016-0928-3

Article  CAS  PubMed  Google Scholar 

Zhang H, Wu S, Hu S, Fan X, Song X, Feng T, Zhou H (2024) Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease. Eur Thyroid J 13. https://doi.org/10.1530/etj-24-0122

Atienza-Mateo B, Prieto-Peña D, Vicente-Rabaneda EF, Blanco R, González-Gay MA, Castañeda S (2022) Utility of Tocilizumab in autoimmune eye diseases. Expert Opin Biol Ther 22:789–799. https://doi.org/10.1080/14712598.2022.2066971

Article  CAS  PubMed  Google Scholar 

Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N (2016) Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 75:1081–1091. https://doi.org/10.1136/annrheumdis-2015-207628

Article  CAS  PubMed  Google Scholar 

Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, Bütikofer L, Seitz M, Reichenbach S (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921–1927. https://doi.org/10.1016/s0140-6736(16)00560-2

Article  CAS  PubMed  Google Scholar 

Kang S, Hamed Azzam S, Minakaran N, Ezra DG (2022) Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev 6:Cd009226. https://doi.org/10.1002/14651858.CD009226.pub3

Article  PubMed  Google Scholar 

Smith TJ (2021) Insulin-Like growth factor pathway and the thyroid. Front Endocrinol (Lausanne) 12:653627. https://doi.org/10.3389/fendo.2021.653627

Article  PubMed  Google Scholar 

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712–716. https://doi.org/10.1046/j.1445-2197.2003.02748.x

Article  PubMed  Google Scholar 

Moola S, Munn Z, Sears K, Sfetcu R, Currie M, Lisy K, Tufanaru C, Qureshi R, Mattis P, Mu P (2015) Conducting systematic reviews of association (etiology): the Joanna Briggs institute’s approach. Int J Evid Based Healthc 13:163–169. https://doi.org/10.1097/xeb.0000000000000064

Article  PubMed  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

Article  PubMed  PubMed Central  Google Scholar 

Perez-Moreiras JV, Alvarez-Lopez A, Gomez EC (2014) Treatment of active Corticosteroid-Resistant graves’ orbitopathy. Ophthal Plast Reconstr Surg 30:162–167. https://doi.org/10.1097/IOP.0000000000000037

Article  PubMed  Google Scholar 

Perez-Moreiras JV, Varela-Agra M, Prada-Sanchez MC, Prada-Ramallal G (2021) Steroid-Resistant Graves’ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience. J Clin Med 10. https://doi.org/10.3390/jcm10040706

Bennedjai A, Bouheraoua N, Gatfosse M, Dupasquier-Fediaevsky L, Errera MH, Tazartes M, Borderie V, Hennocq Q, Della A, Riviere S, Heron E, Fain O, Mekinian A (2022) Tocilizumab versus rituximab in patients with moderate to severe Steroid-resistant graves’ orbitopathy. Ocul Immunol Inflamm 30:500–505. https://doi.org/10.1080/09273948.2020.1808688

Article  CAS  PubMed  Google Scholar 

Boutzios G, Chatzi S, Goules AV, Mina A, Charonis GC, Vlachoyiannopoulos PG, Tzioufas AG (2023) Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe graves’ orbitopathy: an observational study. Front Endocrinol (Lausanne) 14:1186105. https://doi.org/10.3389/fendo.2023.1186105

Article  PubMed  Google Scholar 

Deltour JB, d’Assigny Flamen M, Ladsous M, Giovansili L, Cariou B, Caron P, Drui D, Lebranchu P (2020) Efficacy of rituximab in patients with graves’ orbitopathy: a retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol 258:2013–2021. https://doi.org/10.1007/s00417-020-04651-6

Article  CAS  PubMed  Google Scholar 

Dorado Cortez O, Grivet D, Perrillat N, Gain P, Thuret G (2022) Treatment of corticosteroid-resistant graves’ orbitopathy with Tocilizumab: a single-centre prospective study. Orbit (London). https://doi.org/10.1080/01676830.2022.2119262

Article  Google Scholar 

Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341–352. https://doi.org/10.1056/NEJMoa1910434

Article  CAS  PubMed  Google Scholar 

Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ (2022) Teprotumumab efficacy, safety, and durability in Longer-Duration thyroid eye disease and Re-treatment: OPTIC-X study. Ophthalmology 129:438–449. https://doi.org/10.1016/j.ophtha.2021.10.017

Article  PubMed  Google Scholar 

Eid L, Coste-Verdier V, Longueville E, Ribeiro E, Nicolescu-Catargi B, Korobelnik JF (2020) The effects of rituximab on graves’orbitopathy: A retrospective study of 14 patients. Eur J Ophthalmol 30:1008–1013. https://doi.org/10.1177/1120672119845224

Article  PubMed  Google Scholar 

Habroosh FA, Albrashdi SS, Alsaadi AH, Eatamadi H (2024) Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort. Int Ophthalmol 44:222. https://doi.org/10.1007/s10792-024-03143-4

Article